West Pharmaceutical Services Inc reported second-quarter 2026 results with revenue of $872.3M, net income of $154M and diluted EPS of $2.15, each up versus the prior-year quarter as the company benefited from strong demand for higher‑value proprietary products and devices.Financial Highlights¹ Repo…
Net sales grew 13.8% year-over-year in Q2 2026, led by strong demand for high-value products, especially in Biologics and GLP-1. Operating profit and margins improved, while a cyberattack impacted the West Vantage segment. The company completed a major asset sale and launched a new $1B share repurc…
Q2 2026 saw double-digit revenue and EPS growth, driven by strong performance in HVP components, biologics, and GLP-1s, with margin expansion and robust cash flow. Full-year guidance was raised, reflecting continued momentum and successful recovery from a cyber incident.Based on West Pharmaceutical…
West Pharmaceutical Services entered three long-term agreements with Daikyo Seiko effective July 14, 2026: an amended and restated technology exchange and cross-license, plus two distributorship agreements. The cross-license supports joint development and know-how sharing for closures, vials, syrin…
EXTON, Pa., July 7, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter 2026 financial results before the market opens on Thursday, July 23, 2026, and will…
(13:12 GMT) West Pharma Price Target Raised to $390.00/Share From $350.00 by Keybanc
EXTON, Pa., July 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the company completed the sale and transfer of the manufacturing and supply rights for SmartDose® 3.5mL On-Body Deliver…
